Akebia Therapeutics, Inc. lost $0.02 per diluted share in fiscal year 2025. This represents an increase of 93.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.11 per diluted share. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Akebia Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.02
YoY+93.9%
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
AKBA EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Akebia Therapeutics, Inc.'s diluted earnings per share in fiscal year 2025?
Akebia Therapeutics, Inc. lost $0.02 per diluted share in fiscal year 2025.
How fast is Akebia Therapeutics, Inc.'s diluted earnings per share growing?
Akebia Therapeutics, Inc. (AKBA) diluted earnings per share rose by 93.9% year over year, from -$0.33 to -$0.02 in fiscal year 2025.
What is Akebia Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
Akebia Therapeutics, Inc. (AKBA) reported a loss of $0.11 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Akebia Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Akebia Therapeutics, Inc. (AKBA) reported -$0.03 in diluted earnings per share in Q2 2026.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Akebia Therapeutics, Inc. (AKBA) reported on that line in every period on record.
